Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Attruby
Pharma
BridgeBio’s Attruby cruises toward blockbuster land
As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival ATTR drug Attruby came above analysts’ expectations.
Angus Liu
Aug 11, 2026 11:22am
Sixth Street, KKR invest up to $1B to propel BridgeBio launches
Jul 1, 2026 11:35am
BridgeBio helps spotlight ATTR-CM's hidden impact on women
May 15, 2026 2:57am
Pfizer fends off generic Vyndamax entry until 2031
Apr 28, 2026 4:30pm
Pfizer inks settlements with 2 generic Vyndamax contenders
Apr 27, 2026 11:23am
As questions swirl, Alnylam eyes ATTR market leadership by 2030
Mar 26, 2026 2:08pm
